Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

K36 Therapeutics

Request full access

Clinical stage biopharmaceutical company developing targeted therapies for patients with cancer

Cambridge, United StatesFounded 2021Biotech & Life Sciences

About K36 Therapeutics

K36 Therapeutics, a clinical-stage biopharmaceutical company established in February 2021, focuses on developing targeted therapies for cancers with significant unmet medical needs. The company was founded with the mission to translate the epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics. The President and CEO, Terry Connolly, Ph.D., brings over two decades of biopharmaceutical industry experience to the company, with a background that includes roles in research, development, business development, and executive leadership at companies like Celgene, Roche, and Wyeth. His journey through process chemistry, alliance management, and corporate transactions, including dozens of licensing deals and acquisitions, provides a robust foundation for leading K36.

K36 Therapeutics' business centers on the clinical development of its lead drug candidate, KTX-1001. This orally administered small molecule was exclusively licensed from Novartis and is designed as a selective inhibitor of the histone methyltransferase MMSET (also known as NSD2). The company operates in the precision oncology market, specifically targeting cancers driven by epigenetic dysregulation. The primary client base consists of cancer patients, particularly those with multiple myeloma. K36's business model is typical of a clinical-stage biotech, focusing on advancing its lead asset through clinical trials to eventually secure regulatory approval and commercialization, a process funded by venture capital.

The company has demonstrated considerable fundraising ability, securing a $30 million Series A in December 2021 and a subsequent $70 million Series B in June 2023. The financing rounds were supported by a syndicate of investors including Atlas Venture, F-Prime Capital, Eight Roads Ventures, Nextech Invest, and Bristol-Myers Squibb. These funds are allocated to advance KTX-1001 through its ongoing Phase 1 clinical trials, both as a monotherapy and in combination with existing standard-of-care agents. KTX-1001 is being developed for patients with relapsed and refractory multiple myeloma, with a specific focus on a high-risk subgroup characterized by the t(4;14) genetic translocation, which is present in up to 20% of multiple myeloma patients and is associated with a poor prognosis. The therapy works by inhibiting MMSET, an enzyme that is overexpressed in these patients, thereby aiming to reverse the oncogenic programs that drive tumor growth and resistance to other therapies. In November 2023, the company received the "Overall BioPharma Startup of the Year" award from BioTech Breakthrough, recognizing its work on KTX-1001.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2021
Headquarters
Cambridge, United States
Employees
13
Open positions
None listed
Dealroom signal
29.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jun 2023 $70M $280M Eight Roads Ventures · Bristol-Myers Squibb · Atlas Venture · F-Prime ↗
SERIES AOther financing Dec 2021 $30M $120M F-Prime · Eight Roads Ventures · Atlas Venture ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

K36 Therapeutics website traffic

Latest recorded traffic for K36 Therapeutics is 3.3K monthly website visits, up 83.3% over the last three months. K36 Therapeutics's team declined 27.8% over the past year.

Latest monthly visits3.3K 3-month web change+83.3% 1-year team growth-27.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

K36 Therapeutics in the Cambridge ecosystem

Live from Dealroom

The K36 Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States93.3%
🇨🇦 Canada6.7%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about K36 Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See K36 Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.